StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Down 3.7 %

Shares of DRRX stock opened at $0.76 on Friday. The company’s fifty day moving average price is $0.84 and its 200-day moving average price is $1.16. The stock has a market cap of $23.59 million, a PE ratio of -1.25 and a beta of 0.91. DURECT has a 12 month low of $0.70 and a 12 month high of $1.88.

Institutional Investors Weigh In On DURECT

A hedge fund recently raised its stake in DURECT stock. Geode Capital Management LLC boosted its stake in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the period. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. 28.03% of the stock is currently owned by institutional investors and hedge funds.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.